Characteristics of SLE cohort patients with positive intrapandemic SARS-CoV-2 serology and/or positive RT-PCR
| ID | Date of PCR test | Date serum collected | *Age, years | Sex | Race/ ethnicity | Medications | Cytokine antibodies | ||
| At time of prepandemic serum sample | At time of Intrapandemic serum sample | Prepandemic sample | Intrapandemic sample | ||||||
| SARS-CoV-2 antibody + and RT-PCR+ | |||||||||
| SLE-A | Oct ‘20 | Oct ‘20 | 40–45 | M | Asian | Hydroxychloroquine | Hydroxychloroquine | NRR | NRR |
| SLE-B | Dec ‘20 | Jan ‘21 | 40–45 | F | Asian | Hydroxychloroquine, mycophenolate mofetil, corticosteroids | Hydroxychloroquine, mycophenolate mofetil, belimumab | IL-6, IL-17a | BAFF |
| SLE-C | Apr ‘20 | Oct ‘20 | 45–50 | F | Asian | Hydroxychloroquine, mycophenolate mofetil, corticosteroids | Hydroxychloroquine, mycophenolate mofetil | NRR | NRR |
| SARS-CoV-2 antibody + and RT- PCR not done | |||||||||
| SLE-D | ND | Oct ‘20 | 60–65 | F | White | None | None | IL-6 | IFNy, G-CSF, IL-10, IL-6, Il-22, IL-17a |
| SLE-E | ND | Oct ‘20 | 45–50 | F | White | Hydroxychloroquine, methotrexate | Hydroxychloroquine, methotrexate | NRR | NRR |
| SLE-F | ND | Oct ‘20 | 70–75 | F | White | Hydroxychloroquine | Hydroxychloroquine | NRR | NRR |
| SARS-CoV-2 antibody− and RT-PCR+ | |||||||||
| SLE-G | Dec ‘20 | Nov ‘20 | 20–25 | F | White | Hydroxychloroquine, azathioprine | Hydroxychloroquine, mycophenolate mofetil | NRR | NRR |
| SLE-H | Oct ‘20 | Jun ‘20 | 50–55 | F | Asian | Mycophenolate mofetil, corticosteroids | Methotrexate | NRR | NRR |
| SLE-I | Nov ‘20 | Sep ‘20 | 45–50 | F | White | Hydroxychloroquine | Hydroxychloroquine | IL-22 | NRR |
*Age shown as a 5-year interval to protect confidentiality of individual.
BAFF, B cell activating factor; G-CSF, granulocyte colony stimulating factor; IFN, interferon; IL, interleukin; ND, not done; NRR, normal reference range; RT-PCR, reverse transcriptase PCR assay for SARS-CoV-2 viral RNA.